INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 8 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,549 | -0.5% | 9,295,000 | -21.2% | 3.76% | -4.1% |
| Q2 2023 | $12,609 | -5.2% | 11,795,000 | 0.0% | 3.92% | -6.2% |
| Q1 2023 | $13,303 | +10.6% | 11,795,000 | 0.0% | 4.18% | +16.5% |
| Q4 2022 | $12,029 | -99.9% | 11,795,000 | 0.0% | 3.59% | -7.8% |
| Q3 2022 | $12,434,000 | +23.3% | 11,795,000 | 0.0% | 3.89% | +39.5% |
| Q2 2022 | $10,081,000 | +85.9% | 11,795,000 | +81.5% | 2.79% | +119.4% |
| Q2 2021 | $5,424,000 | +0.1% | 6,500,000 | 0.0% | 1.27% | -3.5% |
| Q1 2021 | $5,420,000 | +41.2% | 6,500,000 | +30.0% | 1.32% | +34.8% |
| Q4 2020 | $3,839,000 | -18.6% | 5,000,000 | 0.0% | 0.98% | -25.6% |
| Q3 2020 | $4,719,000 | – | 5,000,000 | – | 1.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Worth Venture Partners, LLC | 5,814,000 | $5,191,000 | 3.20% |
| DLD Asset Management, LP | 12,500,000 | $11,219,000 | 0.70% |
| Senvest Management, LLC | 5,000,000 | $4,345,000 | 0.51% |
| Context Capital Management, LLC | 985,000 | $863,000 | 0.49% |
| LINDEN ADVISORS LP | 30,755,000 | $26,983,000 | 0.48% |
| SSI INVESTMENT MANAGEMENT LLC | 5,896,000 | $5,014,000 | 0.44% |
| BOOTHBAY FUND MANAGEMENT, LLC | 4,386,000 | $3,812,000 | 0.32% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 16,582,000 | $14,449,000 | 0.31% |
| CSS LLC/IL | 3,825,000 | $3,410,000 | 0.27% |
| Polar Asset Management Partners Inc. | 13,000,000 | $11,372,000 | 0.23% |